Global Systemic Psoriasis Therapeutics Market 2016-2020 – Advent of Biologics With Novel MOA & Cell-Based Strategies – Research and Markets

DUBLIN, July 25, 2016 /PRNewswire/ —

Research and Markets has announced the addition of the “Global Systemic Psoriasis Therapeutics Market 2016-2020” report to their offering.

The report forecasts the global systemic psoriasis therapeutics market to grow at a CAGR of 9.41% during the period 2016-2020.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend resulting in the strong growth of this market is the advent of biologics with novel MOA and cell-based strategies. This market is expected to witness the launch of biologic agents that target the disease pathway specifically, including IL-17/IL-17R receptor inhibitors. Drugs such as brodalumab, guselkumab, and tildrakizumab are undergoing Phase III clinical trials.

According to the report, factors such as the dominance of market by biologics will drive this market’s growth prospects for the near future. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals. These drugs will continue to outperform other pharmaceuticals in terms of product sales as there is an increasing need for innovative products as effective treatment options for a range of indications.

Further, the report states that one challenge impeding this market’s growth is the physician’s reluctance to prescribe biosimilars.

Key vendors:

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Psoriasis: Condition overview

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by type of molecule

PART 09: Market segmentation by mechanism of action

PART 10: Market segmentation by severity of disease

PART 11: Market segmentation by ROA

PART 12: Geographical segmentation

PART 13: Market drivers

PART 14: Impact of drivers

PART 15: Market challenges

PART 16: Impact of drivers and challenges

PART 17: Market trends

PART 18: Vendor landscape

PART 19: Appendix

For more information visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets

Leave a Reply

Your email address will not be published. Required fields are marked *